Pictured above: Dr. Aristotle Voineskos
February 26, 2020 (Toronto) – In a first-of-its-kind study using advanced brain imaging techniques, a commonly used antipsychotic medication was associated with potentially adverse changes in brain structure. This study was the first in humans to evaluate the effects of this type of medication on the brain using a gold-standard design: a double-blind, randomized, placebo-controlled trial.
The study, conducted across several North American centers, and just published in the journal JAMA Psychiatry, could have an immediate impact on clinical practice according to lead author Dr. Aristotle Voineskos, Chief of the Schizophrenia Division, and Head of the Kimel Family Translational Imaging-Genetics Laboratory at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada.
Until the 1990s, antipsychotic medications were primarily administered to people with schizophrenia. But since then their use has expanded to major depression and a range of pediatric, adult and geriatric disorders, including anxiety, insomnia and autism, for which one in five patients are prescribed anti-psychotics.
“Antipsychotic medications remain the cornerstone of treatment for primary psychotic illnesses, but caution should be exercised with their off-label use for other conditions when psychosis is not present. This may be especially true in children and the elderly, when the brain is changing more rapidly,” said Dr. Voineskos.
The study examined both younger adult and older adult patients with major depression who also experience psychosis who were prescribed antipsychotic medications olanzapine and sertraline for 12 to 20 weeks. For those who went into remission, participants were divided into a randomized double-blind phase — where one group continued with both medications and one was given a placebo instead of olanzapine. Magnetic Resonance Imaging (MRI) scans were taken before and after the placebo was introduced.
The study found evidence that sustained use of olanzapine versus a placebo was associated with potentially adverse changes in brain structure, namely a thinning of the cortex. These changes were more prominent in the elderly study participants. But participants who experienced a relapse of psychotic symptoms also had potentially adverse changes in brain structure, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.
“When psychosis is present, the life-threatening effects of untreated illness outweigh any adverse effects on brain structure,” said Dr. Voineskos. “But given that nearly half the patients in the trial sustained remission after switching from olanzapine to placebo, future studies could provide a predictive model for which patients need long-term antipsychotic treatment and which patients can safely discontinue them.”
Funding for the study was provided by the National Institute for Mental Health.
To read the full study click here.
The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, as well as one of the world's leading research centres in its field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental health and addiction issues. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre.
For further information: